1. Changes to US Lovenox prescribing information

   News item 21 January 2013 Pages: 2 - 2

2. Levothyroxine: clinically important differences between products

   Media release 21 January 2013 Pages: 2 - 2

3. Viruses increase alemtuzumab neurological complication risk?

   Clinical study 21 January 2013 Pages: 2 - 2

4. Antipsychotic-induced metabolic disturbances reduce QOL

   Clinical study 21 January 2013 Pages: 3 - 3

5. GI and cardiovascular safety of lumiracoxib on TARGET

   News item 21 January 2013 Pages: 3 - 3

6. Tamoxifen reverses antineoplastic-associated lipid disorders?

   Clinical study 21 January 2013 Pages: 3 - 3

7. Docetaxel-induced hypersensitivity reactions of a nonallergic nature

   Clinical study 21 January 2013 Pages: 4 - 4

8. Ethinylestradiol/cyproterone and VTE: who is at risk?

   Incidence study 21 January 2013 Pages: 4 - 4

9. Further evidence of an association between leflunomide and neuropathy

   Incidence study 21 January 2013 Pages: 4 - 4

10. Leflunomide: high ADR discontinuation rate

    Clinical study 21 January 2013 Pages: 4 - 4

11. PI therapy: risk of lipid disorders elevated during puberty?

    Incidence study 21 January 2013 Pages: 4 - 4

12. Fluvastatin/pravastatin: no significant impact on plasma indinavir

    Clinical study 21 January 2013 Pages: 5 - 5

13. Gemtuzumab ozogamicin: minimal association with SOSVOD

    Incidence study 21 January 2013 Pages: 5 - 5

14. Irinotecan-induced toxicity: polymorphisms and prophylaxis

    Clinical study 21 January 2013 Pages: 5 - 5

15. Leflunomide: no increase in hepatic adverse event risk?

    Incidence study 21 January 2013 Pages: 5 - 5

16. Atenolol/carteolol/timolol

    Case reports 21 January 2013 Pages: 6 - 6

17. Azathioprine

    Case report 21 January 2013 Pages: 6 - 6

18. Betamethasone

    Case report 21 January 2013 Pages: 6 - 6

19. Botulinum toxin

    Case report 21 January 2013 Pages: 6 - 6

20. Carboplatin/docetaxel

    Case report 21 January 2013 Pages: 6 - 7

21. Cefalexin

    Case report 21 January 2013 Pages: 7 - 7

22. Ciclosporin

    Case report 21 January 2013 Pages: 7 - 7

23. Citalopram

    Case reports 21 January 2013 Pages: 7 - 8

24. Clopidogrel

    Case reports 21 January 2013 Pages: 8 - 8

25. Cyclophosphamide/doxorubicin/fluorouracil

    Case report 21 January 2013 Pages: 8 - 8

26. Diclofenac

    Case report 21 January 2013 Pages: 8 - 8

27. Dipyrone

    Case reports 21 January 2013 Pages: 9 - 9

28. Doxycycline

    Case reports 21 January 2013 Pages: 9 - 9

29. Herbal medicines

    Case report 21 January 2013 Pages: 9 - 9

30. Hypericum

    Case report 21 January 2013 Pages: 9 - 10

31. Hydrogen peroxide

    Case report 21 January 2013 Pages: 10 - 10

32. Imiquimod

    Case report 21 January 2013 Pages: 10 - 10

33. Infliximab

    Case report 21 January 2013 Pages: 10 - 10

34. Insulin aspart/insulin lispro

    Case report 21 January 2013 Pages: 10 - 10

35. Insulin lispro

    Case report 21 January 2013 Pages: 11 - 11

36. Interferon-α/peginterferon-α

    Case report 21 January 2013 Pages: 11 - 11

37. Itraconazole

    Case report 21 January 2013 Pages: 11 - 11

38. Leflunomide

    Case report 21 January 2013 Pages: 11 - 12

39. Mesalazine

    Case report 21 January 2013 Pages: 12 - 12

40. Metformin overdose

    Case report 21 January 2013 Pages: 12 - 12

41. Methotrexate

    Case report 21 January 2013 Pages: 12 - 12

42. Mycophenolate mofetil

    Case reports 21 January 2013 Pages: 12 - 13

43. Parabens

    Case report 21 January 2013 Pages: 13 - 13

44. Paracetamol overdose

    Case reports 21 January 2013 Pages: 13 - 13

45. Paracetamol/codeine

    Case report 21 January 2013 Pages: 13 - 13

46. Peginterferon-α

    Case report 21 January 2013 Pages: 13 - 13

47. Pergolide

    Case reports 21 January 2013 Pages: 13 - 14

48. Phenobarbital/phenytoin

    Case report 21 January 2013 Pages: 14 - 14

49. Pioglitazone

    Case report 21 January 2013 Pages: 14 - 14

50. Piperacillin/tazobactam

    Case report 21 January 2013 Pages: 14 - 14